<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04912921</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00012462</org_study_id>
    <nct_id>NCT04912921</nct_id>
  </id_info>
  <brief_title>Effect of Palmitoylethanolamide on Proinflammatory Markers in Adults Recently Diagnosed With COVID-19</brief_title>
  <official_title>Effect of Palmitoylethanolamide on Proinflammatory Markers in Adults Recently Diagnosed With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arizona State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arizona State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial to examine the effect of a food supplement on&#xD;
      proinflammatory cytokines and biomarkers in an adult population recently diagnosed with&#xD;
      COVID-19 who are asymptomatic or experiencing only mild symptoms. The supplement,&#xD;
      palmitoylethanolamide (PEA), is marketed under the trademarked product with increased&#xD;
      bioavailability and format versatility: Levagen+â„¢ (Gencor Pacific Limited, Irvine, CA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inflammation is at the core of many chronic conditions and exacerbates infectious conditions,&#xD;
      and inflammatory responses appear to be key determinants of the severity of COVID-19&#xD;
      infection. Hence, controlling inflammation is considered a key strategy for slowing the&#xD;
      progression of disease and tissue pathology. This research offers a natural, dietary approach&#xD;
      to managing inflammation by reducing the mediators of inflammation. The beneficial effects of&#xD;
      palmitoylethanolamide (PEA) for reducing inflammation is documented in the research&#xD;
      literature. The proposed research will expand this literature in a novel manner. The&#xD;
      investigators propose to demonstrate the efficacy of this dietary supplement in individuals&#xD;
      from a campus population with robust immune protection - those who recently tested positive&#xD;
      for COVID-19 but were asymptomatic or mildly symptomatic. Since a college population is under&#xD;
      many stressors which raise inflammatory profiles during the academic year, and since a&#xD;
      college population is exposed to infectious agents on campus, maintaining strong protective&#xD;
      immune system following a COVID-19 infection is important.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double-blind, randomized, controlled trial</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Palmitoylethanolamide and placebo tablets are identical in appearance and presented to participant in unlabeled opaque containers by investigators blinded to container content.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>IL6 concentration</measure>
    <time_frame>change from baseline at day 28</time_frame>
    <description>interleukin-6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum CRP concentration</measure>
    <time_frame>change from baseline at day 28</time_frame>
    <description>C-reactive protein (high sensitivity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum ferritin concentration</measure>
    <time_frame>change from baseline at day 28</time_frame>
    <description>serum ferritin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum ICAM concentration</measure>
    <time_frame>change from baseline at day 28</time_frame>
    <description>Intercellular Adhesion Molecule 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum NFk-beta concentration</measure>
    <time_frame>change from baseline at day 28</time_frame>
    <description>nuclear factor kappa-light-chain-enhancer of activated B cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum white blood cell differential</measure>
    <time_frame>change from baseline at day 28</time_frame>
    <description>white blood cell differential</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum p-selectin concentration</measure>
    <time_frame>change from baseline at day 28</time_frame>
    <description>cell adhesion molecule</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Inflammation</condition>
  <condition>COVID19</condition>
  <arm_group>
    <arm_group_label>palmitoylethanolamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levagen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>microcrystalline cellulose</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>palmitoylethanolamide</intervention_name>
    <description>4 tablets taken daily (2 in the am and 2 in the pm)</description>
    <arm_group_label>palmitoylethanolamide</arm_group_label>
    <other_name>Levagen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4 tablets taken daily (2 in am and 2 in pm)</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>microcrystalline cellulose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and females 18-65 years old&#xD;
&#xD;
          -  Generally healthy&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Recent positive COVID-19 test (per RT-PCR Test)*&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable or serious illness (e.g. kidney, liver, GIT, heart conditions, diabetes,&#xD;
             thyroid gland function, malignancy, HIV, lung conditions or chronic asthma)&#xD;
&#xD;
          -  Serious mood disorders, neurological disorders such as MS, or cognitive damage&#xD;
&#xD;
          -  Active smokers and/or nicotine or drug abuse&#xD;
&#xD;
          -  Active, regular marijuana or other cannabinoid use, other street/recreational drug use&#xD;
&#xD;
          -  Chronic past and/or current alcohol use (&gt;14 alcoholic drinks week)&#xD;
&#xD;
          -  Allergic to any of the ingredients in active or placebo formula including peanuts,&#xD;
             eggs or turmeric&#xD;
&#xD;
          -  Pregnant or lactating woman&#xD;
&#xD;
          -  People medically prescribed to take drugs that would affect the immune and/or the&#xD;
             inflammatory response&#xD;
&#xD;
          -  People who have had treatment (last 5 years) for cancer, or chronic use of steroids&#xD;
&#xD;
          -  BMI &gt;40&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carol Johnston, PhD</last_name>
    <phone>6024962539</phone>
    <email>carol.johnston@asu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yung Chang, PhD</last_name>
    <phone>(480)965-8672</phone>
    <email>YUNG.CHANG@asu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arizona Biomedical Collaborative</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol S Johnston</last_name>
      <phone>602-496-2539</phone>
      <email>carol.johnston@asu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2021</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>palmitoylethanolamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palmidrol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

